Day: November 14, 2022

Hallmark Financial Services, Inc. Hallmark Financial Services, Inc.DALLAS, Nov. 14, 2022 (GLOBE NEWSWIRE) — Hallmark Financial Services, Inc. (“Hallmark”) (NASDAQ: HALL) today filed its Form 10-Q and announced financial results for the third quarter and nine months ended September 30, 2022.  Third Quarter   Year-to-Date    2022     2021       2022     2021  $ in millions:          Net loss from continuing operations $ (29.3 ) $ (2.0 )   $ (104.9 ) $ (3.9 )Net income from discontinued operations $ 1.1   $ 5.5     $ 4.2   $ 15.4  Net (loss) income $ (28.2 ) $ 3.4     $ (100.8 ) $ 11.6  Operating loss (1) $ (20.6 ) $ (1.6 )   $ (69.2 ) $ (11.1 )           $ per diluted share:          Net loss from continuing operations $ (1.61 ) $ (0.11 )   $ (5.77 ) $ (0.21 )Net income from discontinued operations $ 0.06   $ 0.30     $ 0.23   $ 0.85  Net...

TORONTO, Nov. 14, 2022 (GLOBE NEWSWIRE) — POET Technologies Inc. (“POET” or the “Company”) (TSX Venture: PTK; NASDAQ: POET), the designer and developer of the POET Optical Interposer™, Photonic Integrated Circuits (PICs) and light sources for the data center, tele-communication and artificial intelligence markets, today reported its unaudited condensed consolidated financial results for the third quarter ended September 30, 2022. The Company’s financial results as well as the Management Discussion and Analysis have been filed on SEDAR. All financial figures are in United States dollars (“USD”) unless otherwise indicated. Recent Business Highlights: The Company made significant progress during the three months ended September 30, 2022:Collaborated with Lumentum Holdings Inc. (“Lumentum”), a market-leading designer and...

Initiation of Phase 1/2a endometrial cancer trial expected in 1Q23; preliminary data expected 4Q23 Conference call and live webcast at 4:30 p.m. ET today NEWTOWN, Pa., Nov. 14, 2022 (GLOBE NEWSWIRE) — Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced plans for a Phase 1/2a trial of narazaciclib combined with letrozole in recurrent metastatic low-grade endometrioid endometrial cancer (LGEEC). In addition, the Company reported its third quarter 2022 financial results and provided a business update. “Onconova’s upcoming Phase 1/2a trial has been thoughtfully designed to explore narazaciclib’s potential as a best-in-class therapy when combined with letrozole in recurrent LGEEC,” said Bhavana...

Maroussi, Greece, November 14, 2022 – Pyxis Tankers Inc. (NASDAQ Cap Mkts: PXS) (the “Company” or “Pyxis Tankers”), an international pure play product tanker company, today announced its unaudited results for the three and nine month periods ended September 30, 2022. Summary For the three months ended September 30, 2022, our Revenues, net were $17.0 million. For the same period, our time charter equivalent (“TCE”) revenues were $12.0 million, representing an increase of approximately $8.5 million or 248% over the comparable period in 2021. Our net income attributable to common shareholders for the three months ended September 30, 2022 was $5.1 million, representing an increase of $8.8 million from a net loss of $3.7 million in the comparable period of 2021. For the third quarter of 2022, the net income per share was $0.48 basic and $0.42...

– Over 30% enrollment in ongoing global, pivotal Phase 3 RECOVER trial – – Topline data for Phase 3 RECOVER trial evaluating brilaroxazine for schizophrenia still expected mid-2023 – – $23.2 Million in Cash as of September 30, 2022 – CUPERTINO, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), cardiovascular, metabolic, and inflammatory diseases, today reported financial results for the third quarter ended September 30, 2022 and summarized recent business highlights. “With over 30% enrollment across 15 sites in the United States for our pivotal Phase 3 RECOVER trial, multiple...

Pure-Vu EVS approved for use at 25 hospitals since launch in March 2022, resulting in highest quarterly revenue reported in the Company’s historyRecently named a Sole Source Supplier by the Department of Veteran’s Affairs, with several VA medical centers executing new contracts for Pure-Vu EVS systems under this designationPresented positive clinical data in three abstracts at the American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting that further illustrate how Pure-Vu EVS is enabling physicians to significantly improve visualization during colonoscopy procedures across different settings and patient populationsFORT LAUDERDALE, Fla., Nov. 14, 2022 (GLOBE NEWSWIRE) — Motus GI Holdings, Inc., (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company providing endoscopy solutions that improve...

Continued progress on previously announced strategic process to maximize shareholder value TEL AVIV, Israel and NEW YORK, Nov. 14, 2022 (GLOBE NEWSWIRE) — VBL Therapeutics (Nasdaq: VBLT), a clinical stage biotechnology company developing targeted medicines for immune-inflammatory diseases, today announced financial results for the third quarter ended September 30, 2022, and provided a corporate update. “VBL’s management team and board continue to make good progress on the evaluation of strategic options for the company’s assets, including the GMP manufacturing facility and VB-601 program, with the goal of maximizing shareholder value,” said Dror Harats, M.D., Chief Executive Officer of VBL. “We recently submitted our regulatory filings for a first-in-human clinical trial for the VB-601 program, and expect to initiate this trial...

– Initiated a Phase 1 trial of Icosavax’s first combination bivalent vaccine candidate, IVX-A12, against respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) in older adults – – IVX-A12 is the first bivalent vaccine candidate against both RSV and hMPV to reach clinical stage development – – Cash and cash equivalents, restricted cash, and short-term investments of $222.5M at end 3Q 2022 – SEATTLE, Nov. 14, 2022 (GLOBE NEWSWIRE) — Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases and a vision of creating pan-respiratory vaccines for older adults, today reported financial results for the third...

AUSTIN, Texas, Nov. 14, 2022 (GLOBE NEWSWIRE) — Ideal Power Inc. (“Ideal Power” or the “Company”) (Nasdaq: IPWR), pioneering the development and commercialization of the highly efficient and broadly patented B-TRAN™ bidirectional semiconductor power switch, reported results for its third quarter ended September 30, 2022. “Our progress toward B-TRAN™ commercialization continues as we engaged with another top 10 global automaker, entering into a product development agreement. In addition, we shipped additional B-TRAN™ devices to Diversified Technologies, Inc. (DTI), our Naval Sea Systems Command (NAVSEA) program collaboration partner, in preparation for a full-scale medium voltage direct current (MVDC) circuit breaker demonstration. We also engaged a design partner who is nearing completion of the packaging design...